All In Biotech

Drug Trial Radar · NCT05333458

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

A Phase 2 Study of Atezolizumab With Selinexor in Alveolar Soft Part Sarcoma (AXIOM)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Aug 29, 2022

Primary completion

May 1, 2027

Study completion May 1, 2027

Sponsor

Sponsor type
NIH
First posted
Apr 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type of cancer. The usual approach is defined as care most people get for alveolar soft part sarcoma if they are not part of a clinical study, which includes treatment with radiation, kinase inhibitor drugs, immunotherapy drugs, or chemotherapy drugs. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may help keep cancer cells from growing and may kill them. Giving atezolizumab in combination with selinexor may help shrink tumors and stabilize the cancer in patients with alveolar soft part sarcoma.

Conditions

  • Advanced Alveolar Soft Part Sarcoma
  • Advanced Soft Tissue Sarcoma
  • Metastatic Alveolar Soft Part Sarcoma
  • Refractory Alveolar Soft Part Sarcoma
  • Unresectable Alveolar Soft Part Sarcoma

Interventions

  • AtezolizumabBiological

    Given IV

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Computed TomographyProcedure

    Undergo CT

  • Echocardiography TestProcedure

    Undergo ECHO

  • SelinexorDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: Within first 12 cycles of treatment confirmed 4-8 weeks later (Each cycle = 28 days)

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Keck Medicine of USC Koreatown

    Los Angeles, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland · Recruiting

  • National Institutes of Health Clinical Center

    Bethesda, Maryland · Active not recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • UT MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.